RLAY logo

RLAY Relay Therapeutics, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$18.09
+0.01 (+0.06%)

Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered s…

Market Cap: $4.00Bwww.relaytx.com

Price

No data yet.

Social Signal Score

47
5d
—
30d
50
1 mentions
—
60d
40
2 mentions
—
90d
50
5 mentions
—
news: 5

Analyst Ratings

16 analysts
Buyconsensus
Strong Buy 1Buy 15Hold 0Sell 0Strong Sell 0
Avg price target$28.5+57.5%
Low $26Median $29High $31
Current Consensus

Revenue

$0.00
$-1.0K$27.55M$55.10M$82.65M
Mar 2019Sep 2026

Analyst Estimates

FY2025
$-1.73
$-1.79–$-1.55
6 analysts
FY2026
$-1.55
$-1.61–$-1.50
9 analysts
FY2027
$-1.58
$-1.65–$-1.51
9 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Sanjiv K. Patel
Sector
Healthcare
Industry
Biotechnology
Employees
202
Beta
1.74
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
25.51
www.relaytx.com